• 

  Clinical trial diversity and regulatory decision-making: Implications for dosing, safety and global alignment

  2026-10-06T10:06:00+01:00

• 

  The evolving regulatory framework for clinical data management in the era of decentralised trials

  2026-10-05T15:11:00+01:00

• 

  Lean writing and disclosure-ready principles for clinical trial design and documents

  2026-10-05T14:18:00+01:00

• 

  FDA introduces new pilot programme to accelerate early-stage clinical research

  2026-09-29T09:25:00+01:00

• 

  EMA launches new pre-submission interactions model pilot

  2026-09-28T10:31:00+01:00

• 

  FDA launches final guidance on therapeutic equivalence evaluations

  2026-09-17T14:05:00+01:00

• 

  Regulatory Rapporteur September 2026 – Contents

  2026-09-04T11:39:00+01:00

• 

  Regulatory reforms in China: Strengthening excipient quality and accession to PIC/S

  2026-09-03T15:21:00+01:00

• 

  Modernising India’s drug submissions: Embracing eCTD 4.0 for international regulatory alignment

  2026-09-03T11:11:00+01:00

• 

  Navigating gene therapy development in Japan: The SYNAPSE Model for orchestrating interdependent PMDA consultations

  2026-09-02T14:51:00+01:00

• 

  Managing ATMP lifecycle complexity: Navigating post-approval CMC divergence in Asia-Pacific

  2026-09-02T10:58:00+01:00

• 

  Navigating the Australian Office of the Gene Technology Regulator: A regulatory affairs perspective on clinical trials involving genetically modified organisms

  2026-09-01T15:47:00+01:00

More pharmaceutical content